Audentes Therapeutics (NASDAQ:BOLD) Announces Quarterly Earnings Results, Beats Estimates By $0.07 EPS

Share on StockTwits

Audentes Therapeutics (NASDAQ:BOLD) issued its quarterly earnings data on Thursday. The biotechnology company reported ($1.00) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.07) by $0.07, Briefing.com reports. During the same period last year, the firm earned ($0.97) EPS.

Shares of NASDAQ BOLD traded up $1.49 during trading on Friday, reaching $28.57. The company had a trading volume of 614,500 shares, compared to its average volume of 490,503. The stock has a market capitalization of $1.24 billion, a PE ratio of -8.40 and a beta of 1.77. Audentes Therapeutics has a twelve month low of $17.95 and a twelve month high of $41.65. The stock has a 50-day moving average price of $28.15 and a two-hundred day moving average price of $34.34.

Several brokerages recently issued reports on BOLD. Robert W. Baird began coverage on Audentes Therapeutics in a report on Wednesday, October 2nd. They set an “underperform” rating and a $10.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and set a $48.00 price objective on shares of Audentes Therapeutics in a report on Friday. ValuEngine cut Audentes Therapeutics from a “buy” rating to a “hold” rating in a report on Friday. Zacks Investment Research cut Audentes Therapeutics from a “buy” rating to a “hold” rating in a report on Friday. Finally, William Blair reaffirmed a “hold” rating on shares of Audentes Therapeutics in a report on Wednesday, August 7th. Three investment analysts have rated the stock with a sell rating, three have given a hold rating and eleven have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $40.76.

In other Audentes Therapeutics news, Director Louis G. Lange sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $32.16, for a total transaction of $321,600.00. Following the sale, the director now owns 276,044 shares in the company, valued at $8,877,575.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Matthew R. Patterson sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $34.04, for a total value of $680,800.00. Following the sale, the chief executive officer now owns 135,368 shares in the company, valued at approximately $4,607,926.72. The disclosure for this sale can be found here. Corporate insiders own 5.30% of the company’s stock.

About Audentes Therapeutics

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

Read More: What is the market perform rating?

Earnings History for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.